Gut Liver.
2010 Jun;4(2):212-218.
Virologic Response at 12 Months of Treatment Predicts Sustained Antiviral Efficacy in Patients with Adefovir-Treated Lamivudine-Resistant Chronic Hepatitis B
- Affiliations
-
- 1Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea. je_yeon@hotmail.com
- 2Department of Internal Medicine, Gil Medical Center, Gachon University of Medicine and Science, Incheon, Korea.
- 3GeneMatrix Inc., Yongin, Korea.
- 4Department of Internal Medicine, Konkuk University Hospital, Konkuk University School of Medicine, Seoul, Korea.
Abstract
- BACKGROUND/AIMS
The aim of our study was to define the potential role of virologic response at 12 months of treatment (VR12) in predicting subsequent virologic and clinical outcomes in adefovir (ADV)-treated lamivudine-resistant chronic hepatitis B.
METHODS
Two hundred and four patients with lamivudine-resistant chronic hepatitis B virus (HBV) treated with ADV monotherapy were included. Serum HBV DNA was quantified by real-time polymerase chain reactions. VR12 was defined as a HBV DNA level of less than 4 log10 copies/mL after 12 months of ADV treatment.
RESULTS
VR12 was observed in 110 of the 204 patients (54%). The mean HBV DNA reductions from baseline after 12 months of ADV treatment were 3.8 and 1.9 log10 copies/mL in patients with and without VR12, respectively (p<0.001). The hepatitis B "e" antigen (HBeAg) seroconversion rates in patients with and without VR12 were 32% and 14% at 12 months treatment, respectively (p=0.018), and 40% and 27% at 24 months of treatment (p=0.032). The genotypic mutation rates to ADV in patients with and without VR12 were 0% and 6% at 12 months of treatment, respectively (p=0.033), and 21% and 42% at 24 months (p=0.012). The rates of viral breakthrough in patients with and without VR12 were 0% and 7% at 12 months of treatment, respectively (p=0.072), and 9% and 25% at 24 months (p=0.006).
CONCLUSIONS
Patients without VR12 may need to switch to or add on other potent antiviral drugs in their medical regimens.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Efficacy of New Anti-viral Agent in the Treatment of Chronic Hepatitis B
- Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients
- Anti-viral Treatment of Chronic Hepatitis B
- Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients
- Antiviral Treatment of Chronic Hepatitis B and C: Current Update
